Lilly’s Mounjaro Cuts Risk of Heart Attack, Strokes in Study

Eli Lilly's Mounjaro met its non-inferiority endpoint in a head-to-head cardiovascular outcomes study against its older drug Trulicity, confirming it as an acceptable alternative for reducing heart attack and stroke risks. However, the trial failed to demonstrate Mounjaro's superiority, which was a key investor expectation, leading Bloomberg Intelligence to anticipate a negative market reaction despite the drug meeting its primary objective.

Analysis

Eli Lilly & Co.'s (LLY) blockbuster drug Mounjaro successfully met its primary endpoint in its largest and longest head-to-head trial, demonstrating non-inferiority to its older drug, Trulicity, in reducing the risk of major cardiovascular events like heart attacks and strokes. While achieving this target confirms Mounjaro as an acceptable alternative, the study critically failed to demonstrate superiority, an outcome investors had widely anticipated. This result dashes hopes that Mounjaro would offer a meaningfully better cardiovascular risk reduction profile compared to Trulicity. As noted by a Bloomberg Intelligence analyst, the absence of a superiority claim is expected to be received negatively by the market, as the investment thesis for many was predicated on Mounjaro establishing a clear clinical advantage that would further accelerate its market share gains and justify its premium positioning.

Key Decisions for Investors

• Investors should anticipate potential near-term negative pressure on Eli Lilly's stock as the market digests the trial results, which fell short of the key superiority expectation.
• It is prudent to re-evaluate long-term growth models for Mounjaro, as the lack of demonstrated cardiovascular superiority over the older Trulicity may temper its competitive differentiation and peak sales potential.
• Monitor for management commentary on the commercial implications of these findings and any future trial data that could establish other points of clinical or market advantage for Mounjaro.